Assess Risk of Joint Damage

Identify the risk for radiographic progression with Vectra DA

High Vectra DA scores identified patients with early RA at higher risk of joint damage, while low to moderate scores identified a lower risk. Early RA patients with high Vectra DA scores at baseline were seven times as likely to have rapid radiographic progression (Δ SHS >5) over one year as those with low or moderate Vectra DA scores.¹

Only one patient (1/34) with a low or moderate Vectra DA score at baseline experienced radiographic progression (Δ SHS >5) over 1 year.¹

 

rapid-radiographic-progression

SHS = Van der Heijde-modified Sharp Score
*The P value 0.008 represents low/moderate vs high Vectra DA score. The P value for moderate vs high Vectra DA score is 0.021.¹

 

Vectra DA detects disease activity that other assessments do not

Vectra DA better discriminated the risk for radiographic progression compared with CRP, ESR and DAS28-ESR.¹

ra-disease-progression-graphs

SHS = Van der Heijde-modified Sharp Score

 

Reduction of high baseline Vectra DA scores was associated with a decreased risk of joint damage²

Patients who lowered their Vectra DA scores from baseline to Year 1 were less likely to experience rapid radiographic progression from Year 1 to Year 2 than those whose Vectra DA scores remained high.

vectra-da-scores

 

The role of Vectra DA in assessing the risk of radiographic progression

 


References:
* 1. Hambardzumyan K, Bolce R, Saevarsdottir S, et al. Pretreatment multi-biomarker disease activity score and radiographic progression in early RA: results from the SWEFOT trial [published online ahead of print May 8, 2014]. Ann Rheum Dis 2014;0:1–8. doi:10.1136/annrheumdis-2013-204986.

* 2. Hambardzumyan K, Bolce R, Saevarsdottir S, et al. In early RA, the multi-biomarker disease activity score at different time-points is predictive of subsequent radiographic progression. Poster presented at: EULAR Annual European Congress of Rheumatology; June 11-14, 2014; Paris, France. Poster SAT0045.

* †MTX nonresponders (all patients received triple therapy or infliximab).